German arms maker shares jump on hopes for higher defence spending
March 3 (Reuters) - Shares in German arms makers were set to open sharply higher on Monday boosted by the prospect of higher defence spending after European leaders agreed to draw up a peace plan for Ukraine.
At a summit in London on Sunday, just two days after Ukrainian President Volodymyr Zelenskiy clashed with U.S. President Donald Trump, European leaders agreed they must spend more on defence.
Separately, Reuters reported that parties in talks to form Germany's new government are weighing setting up a defence fund.
Hensoldt HAGG.DE, which provides sensor systems for the Eurofighter, jumped 22% in early trade while Leopard 2 tanks maker Rheinmetall RHMG.DE gained 19%.
Thyssenkrupp TKAG.DE, MTU Aero Engines MTXGn.DE and Renk R3NK.DE were up between 3% and 16%.
Related Articles
BoE August Rate Decision Commentary: Where Next for the Pound?
TradingKey - On 7 August 2025, the Bank of England (BoE) lowered its benchmark interest rate from 4.25% to 4%, aligning with broad market expectations. Notably, the decision sparked significant division within the committee, requiring two rounds of voting to pass.
MP Materials 2Q25 Earnings Comment: Going up the Value Chain
TradingKey - MP Materials released its earnings for the second quarter of the fiscal 2025 on August 7th after the bell.The smaller loss and the better revenue were surely welcomed by investors, and the stock is up 8.50% in the post-bell session.
Eli Lilly’s Q2 2025 Triumph: Soaring Revenue, Plunging Stock – What’s Behind the Paradox?
TradingKey - Eli Lilly released its Q2 2025 financial results, demonstrating impressive financial performance. However, despite the stellar results, its stock price plummeted by over 14%, closing at approximately $640, down more than 30% from its yearly high..jpg)
Caution on Short-Term Downside Risks for U.S. Stock Market
TradingKey - Last Friday, the U.S. Labor Department sharply revised downward its May and June nonfarm payroll figures by a combined 258,000 jobs, a reduction exceeding 90%. Meanwhile, July’s payroll increase came in at just 73,000, falling short of the 100,000 forecast.
From Ozempic to Wegovy: Growth and Risks Behind Novo Nordisk’s Q2 Performance
TradingKey - Novo Nordisk achieved revenue of $11.67 billion in Q2 of the 2025 fiscal year, a 19% increase year-over-year, but it fell short of market expectations. Growth was primarily driven by strong performance in obesity care and rare diseases.
